HER2陽性乳がんの進行した患者にとって最適な第一線療法とは? 体系的なレビューとネットワークメタ解析
Chenxi Wei1, Qi Zheng1, Xinchun Ma1
1Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Journal of cancer research and therapeutics
|September 4, 2025
まとめ
タクサン,トラストズマブ,そしてピロチニブ (THPyr) の治療法は,HER2陽性乳がんの進行のない生存率が最も高いことを示しています. この組み合わせは最適な第一線治療法であり,他の治療法と比べると安全性が高い.
科学分野:
- 腫瘍学
- 薬理学について
- 臨床試験
背景:
- トラストズマブのような抗HER2薬は,転移性HER2陽性乳がんの生存率を向上させた.
- 複数の抗HER2の組み合わせから最適な第一線治療を選択することは,依然として課題です.
研究 の 目的:
- HER2陽性の転移性乳がんの最適な第一線治療法を決定する.
- ネットワークメタアナリシスを用いて様々な抗HER2療法の有効性と安全性を比較する.
主な方法:
- 2023年3月16日までのPubMed,Embase,Cochrane Library,および主要な腫瘍学会議の要約を体系的に検索する.
- 3, 887人の参加者を含む19件のランダム化対照試験 (RCT) を含む.
- PFS,全生存率,客観的応答率 (ORR),重篤な有害事象 (≥3AEs) に基づいて14の治療レジメンをランク付けするためのネットワークメタ分析.
主要な成果:
- タクサン/ パクリタキセル/ ドクタキセル + トラストズマブ + ピロチニブ (THPyr) 療法は,PFSの最も顕著な効果を示した.
- THPyrはORRで最高にランクされ,次にTHPとTdmPが続きました. THPは最も好ましいOSを提供しました.
- THPyrは,異なるホルモン受容体状態において有効性を示し,他の治療法と比較して有意な安全性差異はなかった.
結論:
- THPyr療法は,HER2陽性乳がんの進行期における最適な第一線治療法である.
- THPyrは,優れたPFSとORRを提供する新しいファーストラインオプションとして承認される可能性があります.
- この研究は,HER2陽性乳がんの治療における臨床的意思決定に役立つ貴重なデータを提供します.
さらに関連する動画
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.8K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.9K
関連する概念動画
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
